Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 11 Rectal Neoplasms 5 Colorectal Neoplasms 5 Stomach Neoplasms 3 Neoplasm Metastasis 3 Nasopharyngeal Carcinoma 3 Carcinoma, Non-Small-Cell Lung 3 Triple Negative Breast Neoplasms 2 Lung Neoplasms 2 Spinocerebellar Degenerations 1 Solid Tumor 1 Resectable NSCLC 1 Recurrence 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Meningeal Carcinomatosis 1 MSI-H 1 Lymphoma, T-Cell, Peripheral 1 HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Resectable NSCLC × sintilimab × 90 days × Clear all

NCT07492342 2026-03-25

K-NADIR

The First Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting

Resectable NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡